PEMAZYRE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pemazyre, and when can generic versions of Pemazyre launch?
Pemazyre is a drug marketed by Incyte Corp and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and thirty-six patent family members in thirty-eight countries.
The generic ingredient in PEMAZYRE is pemigatinib. One supplier is listed for this compound. Additional details are available on the pemigatinib profile page.
DrugPatentWatch® Generic Entry Outlook for Pemazyre
Pemazyre was eligible for patent challenges on April 17, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PEMAZYRE?
- What are the global sales for PEMAZYRE?
- What is Average Wholesale Price for PEMAZYRE?
Summary for PEMAZYRE
| International Patents: | 136 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 7 |
| Patent Applications: | 58 |
| Drug Prices: | Drug price information for PEMAZYRE |
| What excipients (inactive ingredients) are in PEMAZYRE? | PEMAZYRE excipients list |
| DailyMed Link: | PEMAZYRE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PEMAZYRE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PEMAZYRE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Incyte Biosciences International Sàrl | Phase 2 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
Pharmacology for PEMAZYRE
Paragraph IV (Patent) Challenges for PEMAZYRE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| PEMAZYRE | Tablets | pemigatinib | 4.5 mg, 9 mg and 13.5 mg | 213736 | 1 | 2024-04-17 |
US Patents and Regulatory Information for PEMAZYRE
PEMAZYRE is protected by nine US patents and four FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PEMAZYRE is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PEMAZYRE
Substituted tricyclic compounds as FGFR inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS
Substituted tricyclic compounds as FGFR inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting PEMAZYRE
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for PEMAZYRE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Incyte Biosciences Distribution B.V. | Pemazyre | pemigatinib | EMEA/H/C/005266 Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. |
Authorised | no | no | yes | 2021-03-26 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for PEMAZYRE
When does loss-of-exclusivity occur for PEMAZYRE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1424
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROPLASTO (FGFR)
Estimated Expiration: ⤷ Sign Up
Patent: 7823
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROBLASTO (FGFR)
Estimated Expiration: ⤷ Sign Up
Patent: 2006
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DE RECEPTORES DEL FACTOR DE CRECIMIENTO DEL FIBROBLASTO (FGFR)
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 13287176
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 19200066
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 20270520
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 22291504
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2014030812
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 76689
Patent: COMPOSES TRICYCLIQUES SUBSTITUES UTILISES COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 49881
Patent: COMPOSES TRICYCLIQUES SUBSTITUES UTILISES COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 14003355
Patent: Compuestos tricíclicos sustituidos, inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr); composicion farmaceutica que los comprende; metodo para tratar cancer, trastorno mieloproliferativo, trastorno esqueletico, trastorno de hipofosfatemia, entre otros.
Estimated Expiration: ⤷ Sign Up
Patent: 17001984
Patent: Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
Estimated Expiration: ⤷ Sign Up
China
Patent: 4507943
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 7383009
Patent: 作为FGFR抑制剂的取代的三环化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 7652289
Patent: 作为FGFR抑制剂的取代的三环化合物 (Substituted tricyclic compounds as FGFR inhibitors)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 40375
Patent: Compuestos tricíclicos sustituidos como inhibidores del fgfr
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 140577
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0170430
Estimated Expiration: ⤷ Sign Up
Patent: 0190007
Estimated Expiration: ⤷ Sign Up
Patent: 0201966
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 18744
Estimated Expiration: ⤷ Sign Up
Patent: 21299
Estimated Expiration: ⤷ Sign Up
Patent: 23631
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 61595
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 15001225
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS
Estimated Expiration: ⤷ Sign Up
Patent: 22091792
Patent: COMPUESTOS TRICÍCLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROPLASTOS
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 6592
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 1590005
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR
Estimated Expiration: ⤷ Sign Up
Patent: 2091923
Patent: ЗАМЕЩЕННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ FGFR
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 61595
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 22273
Patent: COMPOSÉS TRICYCLIQUES SUBSTITUÉS SERVANT D'INHIBITEURS DES FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 12326
Patent: 作為 抑制劑的取代的三環化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS FGFR)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 31916
Estimated Expiration: ⤷ Sign Up
Patent: 42374
Estimated Expiration: ⤷ Sign Up
Patent: 52195
Estimated Expiration: ⤷ Sign Up
Patent: 100035
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6078
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 6976
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 6433
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 2622
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷ Sign Up
Patent: 9834
Patent: המרת תרכובות טריסייקליות כמעכבות fgfr (Substituted tricyclic compounds as fgfr inhibitors)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 01321
Estimated Expiration: ⤷ Sign Up
Patent: 36665
Estimated Expiration: ⤷ Sign Up
Patent: 45863
Estimated Expiration: ⤷ Sign Up
Patent: 11946
Estimated Expiration: ⤷ Sign Up
Patent: 00170
Estimated Expiration: ⤷ Sign Up
Patent: 92096
Estimated Expiration: ⤷ Sign Up
Patent: 15521600
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物
Estimated Expiration: ⤷ Sign Up
Patent: 17222709
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 18135377
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 19178156
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 20143142
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 23027344
Patent: ＦＧＦＲ阻害剤としての置換三環式化合物
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 861595
Estimated Expiration: ⤷ Sign Up
Patent: 2021519
Estimated Expiration: ⤷ Sign Up
Patent: 61595
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 1375
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 8363
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 9293
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 14015192
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Patent: 22000517
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR). (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 651
Patent: SUBSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 300
Patent: SUPSТITUISANA TRICIKLIČNA JEDINJENJA КАО INHIBIТORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1131
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2747
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 0134
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 3274
Patent: Substituted tricyclic compounds as fgfr inhibitors
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 21034
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 150684
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷ Sign Up
Patent: 190736
Patent: COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR)
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 014502772
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 016502133
Patent: SUBSTITUTED TRICYCLE COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 019502809
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 61595
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 61595
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 908
Patent: SUBSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 514
Patent: SUPSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 089
Patent: SUPSTITUISANA TRICIKLIČNA JEDINJENJA KAO INHIBITORI FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201610416T
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 201408238W
Patent: SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 61595
Estimated Expiration: ⤷ Sign Up
Patent: 76170
Estimated Expiration: ⤷ Sign Up
Patent: 95367
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2140426
Estimated Expiration: ⤷ Sign Up
Patent: 2406771
Estimated Expiration: ⤷ Sign Up
Patent: 2556118
Estimated Expiration: ⤷ Sign Up
Patent: 150036044
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 200093696
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (FGFR SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 220080213
Patent: FGFR 억제제로서 치환된 트리사이클릭 화합물 (FGFR SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 18003
Estimated Expiration: ⤷ Sign Up
Patent: 04744
Estimated Expiration: ⤷ Sign Up
Patent: 32497
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 06953
Estimated Expiration: ⤷ Sign Up
Patent: 69529
Estimated Expiration: ⤷ Sign Up
Patent: 01156
Estimated Expiration: ⤷ Sign Up
Patent: 1402574
Patent: Substituted tricyclic compounds as FGFR inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 2124382
Patent: Substituted tricyclic compounds as fibroblast growth factor receptor inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 2241898
Patent: Substituted tricyclic compounds as fibroblast growth factor receptor inhibitors
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 7347
Patent: ЗАМІЩЕНІ ТРИЦИКЛІЧНІ СПОЛУКИ ЯК ІНГІБІТОРИ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 5503
Patent: ЗАМІЩЕНІ ТРИЦИКЛІЧНІ СПОЛУКИ ЯК ІНГІБІТОРИ FGFR (SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering PEMAZYRE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 104507943 | Substituted tricyclic compounds as FGFR inhibitors | ⤷ Sign Up |
| Peru | 20150684 | COMPUESTOS TRICICLICOS SUSTITUIDOS COMO INHIBIDORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE FIBROBLASTOS (FGFR) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2019213544 | ⤷ Sign Up | |
| South Korea | 102406771 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PEMAZYRE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2861595 | C02861595/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: PEMIGATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68143 13.07.2021 |
| 2861595 | PA2021519 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
| 2861595 | 132021000000140 | Italy | ⤷ Sign Up | PRODUCT NAME: PEMIGATINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(PEMAZYRE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1535, 20210329 |
| 2861595 | 122021000054 | Germany | ⤷ Sign Up | PRODUCT NAME: PEMIGATINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
